November 11, 2009 - Non-invasive treatment with the ExAblate Magnetic Resonance-guided Focused Ultrasound (MRgFUS) system by InSightec Ltd. reduces risk in treating symptomatic uterine fibroids, according to a study published in the November issue of Ultrasound in Obstetrics and Gynecology.
A prospective study of 192 patients at 14 different medical centers across the United States, Israel, the United Kingdom and Germany, showed that MRgFUS was associated with significantly fewer adverse events in comparison with hysterectomy patients. Similarly, recovery times were much faster for MRgFUS, with an average of only one day away from work as opposed to 6 weeks for hysterectomy.
In another report published in Ultrasound in Obstetrics and Gynecology, a separate study shows the positive correlation in the volume reduction of the fibroid to symptom improvement after two years.
Prof. Wladyslaw M. Gedroyc, St. Mary's Hospital, Imperial College Healthcare Trust, London, UK, wrote in an Opinion published in the November issue: "MRgFUS works quickly with very few side effects and that patients can return to normal function almost immediately after treatment. We also know that the larger the area of ablation that can be produced in the targeted fibroids, the better the symptomatic response and the less the need for other fibroid interventions, and that when the early symptomatic response is highly effective, long-term improvement of symptoms is almost invariably seen."
For more information: www.insightec.com
July 25, 2024 
